Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
What Lab Results and Scans Do I Need Before Starting Lu-177 DOTATATE — and What Do the Numbers Actually Mean for a Well-Differentiated Neuroendocrine Tumor?
Before you can start Lu-177 DOTATATE therapy, your care team needs a clear picture of your tumor, your organs, and your overall health. This plain-language guide walks you through every test — and explains what the numbers actually mean for your eligibility and safety.
What Do the Latest Clinical Trial Results Tell Us About Lu-177 PSMA Therapy for Stage 4 Prostate Cancer — and What Do They Mean for My Treatment?
The VISION and PSMAfore trials have reshaped how doctors use Lu-177 PSMA therapy for advanced prostate cancer. Here is what the evidence shows, in plain language, and what it may mean for you.
What Integrative Therapies and Lifestyle Changes Can Support Lu-177 PSMA Treatment in Men with PSMA-Positive Prostate Cancer?
Lu-177 PSMA therapy works best when your whole body is supported. Learn which evidence-informed lifestyle changes — from diet and exercise to mind-body practices — may help men with PSMA-positive prostate cancer feel better and stay stronger during treatment.
Will Lu-177 DOTATATE Make My Neuroendocrine Tumor Symptoms Better? What Patients with Metastatic NETs Can Expect
Many patients with metastatic neuroendocrine tumors ask one question above all else: will this treatment actually make me feel better? Here is what the clinical evidence says about Lu-177 DOTATATE and symptom relief.
What Side Effects Should I Expect from Lu-177 DOTATATE for a Gastroenteropancreatic Neuroendocrine Tumor — and How Can I Manage Them?
Lu-177 DOTATATE (PRRT) is an effective therapy for GEP-NETs, but it does cause side effects. Learn what to expect — from nausea and fatigue to kidney and blood-count changes — and practical ways to manage each one.
Why India is becoming the world's destination for Lutetium therapy.
As Lu-177 therapy demand has grown globally, the supply landscape has shifted. India, with its decades-long nuclear medicine infrastructure and competitive pricing, has emerged as one of the world's most accessible high-quality destinations for Lutetium therapy. Here's the bigger picture — and what it means for international patients planning treatment.
My Prostate Cancer Stopped Responding to Hormone Therapy — What Are My Options Before Chemotherapy?
When hormone therapy stops controlling prostate cancer, it can feel like the ground has shifted. But there are real options between hormone therapy and chemotherapy — including targeted radiotherapy, PARP inhibitors, and a newer radioligand approach. Here is a plain-language guide to help you understand what comes next.
How Do I Tell My Family I Have Lymphoma? A Guide to Starting the Conversation
A lymphoma diagnosis brings a flood of emotions — and one of the hardest early steps is telling the people you love. This guide offers practical, compassionate advice on how to start that conversation, what to say to children, and how to handle the reactions that follow.
Managing Fatigue During Lu-177 DOTATATE Therapy: What Patients Can Actually Do
Fatigue is one of the most common side effects of Lu-177 DOTATATE therapy for neuroendocrine tumors. This guide explains why it happens and shares practical, evidence-based steps that may help you feel better during treatment.
Does Lu-177 DOTATATE Still Work If My Carcinoid Tumor Has Spread to My Liver? What the Evidence Says
If your carcinoid tumor has spread to your liver, you may wonder whether Lu-177 DOTATATE (PRRT) can still help. The short answer, based on current research, is yes — but how well it works may depend on how much of the liver is involved and other key factors.
Can I hug my grandchildren after a Lutetium infusion?
This is, hands down, the most common question patients ask us. The short answer is yes — with reasonable precautions for about 3–5 days. The longer answer explains why these precautions are simpler than most patients fear.
What Happens During a Lu-177 PSMA Infusion? A Step-by-Step Guide for First-Time Patients
Feeling nervous about your first Lu-177 PSMA infusion? This plain-language guide walks you through every step — from the blood tests before your appointment to the radiation safety rules you follow at home — so you know exactly what to expect.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.